Trials / Completed
CompletedNCT04169711
Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
A Phase 1b Dose-Finding Study of ARO-HIF2 in Patients With Advanced Clear Cell Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 26 (actual)
- Sponsor
- Arrowhead Pharmaceuticals · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and efficacy of ARO-HIF2 injection (also referred to as ARO-HIF2) and to determine the recommended Phase 2 dose in the treatment of patients with advanced clear cell renal cell carcinoma (ccRCC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ARO-HIF2 | Multiple doses of ARO-HIF2 by intravenous infusion |
Timeline
- Start date
- 2020-08-17
- Primary completion
- 2022-01-24
- Completion
- 2022-07-22
- First posted
- 2019-11-20
- Last updated
- 2025-10-09
Locations
5 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04169711. Inclusion in this directory is not an endorsement.